{"classes":[{"categories":[{"measurements":[{"comment":"NA means median, upper limit, and lower limit not reached at time of data cut-off due to insufficient number of participants with an event.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA means median, upper limit, and lower limit not reached at time of data cut-off due to insufficient number of participants with an event.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA means median, upper limit, and lower limit not reached at time of data cut-off due to insufficient number of participants with an event.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"81"},{"groupId":"OG002","value":"60"}],"units":"Participants"}],"description":"OS is the time from the first dose to death due to any cause. The Kaplan-Meier method was used to estimate the survival curve, separately by Cohort with missing data censored at last assessment.","dispersionType":"Full Range","groups":[{"description":"Participants with RRcHL who failed to achieve a response or progressed after auto-SCT and have relapsed after treatment with or failed to respond to BV post auto-SCT received pembrolizumab, 200 mg, intravenously (IV) every 3 weeks (Q3W) on Day 1 of each 21-day cycle up to 35 cycles, for up to 24 months.","id":"OG000","title":"Cohort 1"},{"description":"Participants with RRcHL who were unable to achieve Complete Response (CR) or Partial Response (PR) to salvage chemotherapy and did not receive auto-SCT, but have relapsed after treatment with or failed to respond to BV received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle up to 35 cycles, for up to 24 months.","id":"OG001","title":"Cohort 2"},{"description":"Participants with RRcHL who failed to achieve a response to or progressed after auto-SCT and have not received BV post auto-SCT received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle, up to 35 cycles for up to 24 months. These participants may or may not have received BV as part of primary treatment or salvage treatment.","id":"OG002","title":"Cohort 3"}],"paramType":"MEDIAN","populationDescription":"All allocated participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 99 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}